Breaking News Instant updates and real-time market news.

NTLA

Intellia Therapeutics

$16.62

-0.64 (-3.71%)

, EDIT

Editas Medicine

$16.28

-1.02 (-5.90%)

16:13
07/17/17
07/17
16:13
07/17/17
16:13

Intellia Therapeutics initiated with a Perform at Oppenheimer

Oppenheimer analyst Leah Rush Cann stated Intellia Therapeutics (NTLA) with a Perform rating saying the company is currently in a weaker patent position than competitor Editas Medicine (EDIT). The analyst, however, believes Intellia has the strongest partners among the CRISPR-based companies.

NTLA

Intellia Therapeutics

$16.62

-0.64 (-3.71%)

EDIT

Editas Medicine

$16.28

-1.02 (-5.90%)

NTLA Intellia Therapeutics
$16.62

-0.64 (-3.71%)

05/31/17
JEFF
05/31/17
NO CHANGE
Target $33
JEFF
Buy
Intellia Therapeutics weakness a buying opportunity, says Jefferies
Jefferies analyst Maury Raycroft said weakness in Intellia Therapeutics shares in reaction to an article published in Nature Methods is a buying opportunity. The analyst said the story is "flawed overall" as it draws conclusions based on assessment of two experiments in mice that have different genetic makeup compared to a single control mouse, combined with other genetic variables, that may explain the article's conclusions. Raycroft said the story should not impact shares and reiterates his Buy rating and $33 price target on Intellia Therapeutics.
05/03/17
FBCO
05/03/17
NO CHANGE
Target $24
FBCO
Outperform
Intellia Therapeutics price target lowered to $24 from $39 at Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target for Intellia Therapeutics to $24 from $39 saying that while she still likes it, big upside is likely capped until the company moves forward toward proof of concept. Young reiterates an Outperform rating on the shares.
03/28/17
CHDN
03/28/17
INITIATION
Target $19
CHDN
Buy
Intellia Therapeutics initiated with a Buy at Chardan
Chardan analyst Madhu Kumar initiated Intellia Therapeutics with a Buy and a $19 price target saying its relative under-valuation in the CRISPR sector overrides possible downside from the company's IP weakness.
02/16/17
JEFF
02/16/17
NO CHANGE
Target $33
JEFF
Buy
Intellia IP position largely unchanged after ruling, says Jefferies
After management hosted a conference call, Jefferies analyst Gena Wang says Intellia Therapeutics (NTLA) remains well positioned for potential broad intellectual property issuance given claims already deemed allowable by patent examiners. Despite yesterday's "no interference" ruling, the company's U.S. IP position is largely unchanged, Wang tells investors in a research note. She continues to believe cross-licensing could be the eventual path for both Intellia and Editas Medicine (EDIT). The analyst has a Buy rating on Intellia with a $33 price target.
EDIT Editas Medicine
$16.28

-1.02 (-5.90%)

07/13/17
RHCO
07/13/17
INITIATION
Target $17
RHCO
Hold
Editas Medicine initiated with a Hold at SunTrust
SunTrust analyst Peter Larson initiated Editas Medicine with a Hold and a $17 price target.
03/28/17
CHDN
03/28/17
INITIATION
Target $65
CHDN
Buy
Editas Medicine initiated with a Buy at Chardan
Chardan analyst Madhu Kumar initiated Editas Medicine with a Buy and a $65 price target due to its IP breadth and strength provides upside potential through both internal and partnered program opportunities.
02/16/17
PIPR
02/16/17
NO CHANGE
Target $21
PIPR
Overweight
Piper's Schimmer calls CRISPR selloff 'major overreaction'
Piper Jaffray analyst Joshua Schimmer views yesterday's selloff in shares of CRISPR Therapeutics (CRSP) as a "major overreaction." The stock closed yesterday down 8%, or $1.36, to $15.90 after the patent office did not allow the patent interference with UC Berkeley versus Broad Institute over a Crispr/Cas-9 patent. Now that it's deemed patentable, CRISPR will move forward to get its own claims issued and likely move towards a second interference, Schimmer tells investors in a research note. CRISPER and Intellia Therapeutics (NTLA) are essentially litigation partners against the Broad, and now have the chance to win by knocking out Editas Medicine's (EDIT) single-guide tracr patent or by showing it was the first to invent and reduce to practice the application in eukaryotes, the analyst contends. Schimmer says he can't understand why Editas' valuation is higher than CRISPR's. He believes it should be the opposite. The analyst keeps an Overweight rating on CRISPR with a $21 price target.

TODAY'S FREE FLY STORIES

EGRX

Eagle Pharmaceuticals

$70.04

-2.76 (-3.79%)

12:36
07/26/17
07/26
12:36
07/26/17
12:36
Hot Stocks
Breaking Hot Stocks news story on Eagle Pharmaceuticals »

Eagle says FDA asks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

CMG

Chipotle

$346.19

-2.427 (-0.70%)

12:36
07/26/17
07/26
12:36
07/26/17
12:36
Periodicals
Expert calls Chipotle's FDA criminal subpoena 'highly unusual,' NY Post reports »

The subpoena from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGRX

Eagle Pharmaceuticals

$70.04

-2.76 (-3.79%)

12:36
07/26/17
07/26
12:36
07/26/17
12:36
Hot Stocks
Eagle Pharmaceuticals receives complete response letter from FDA on Ryanodex »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

IVPAF

Ivanhoe Mines

$3.89

0.1263 (3.36%)

12:33
07/26/17
07/26
12:33
07/26/17
12:33
Conference/Events
Ivanhoe Mines management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

WYNN

Wynn Resorts

$138.98

0.45 (0.32%)

12:30
07/26/17
07/26
12:30
07/26/17
12:30
Options
Wynn Resorts calls active as shares fall on earnings »

Wynn Resorts calls active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGRX

Eagle Pharmaceuticals

$70.04

-2.76 (-3.79%)

12:29
07/26/17
07/26
12:29
07/26/17
12:29
Hot Stocks
Breaking Hot Stocks news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

FLY

Fly Leasing

$13.94

-0.04 (-0.29%)

12:27
07/26/17
07/26
12:27
07/26/17
12:27
Conference/Events
Fly Leasing management to meet with RBC Capital »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 10

    Aug

SIRI

SiriusXM

$5.39

0.01 (0.19%)

12:25
07/26/17
07/26
12:25
07/26/17
12:25
Options
Sirius XM call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 05

    Sep

AKAM

Akamai

$53.28

0.91 (1.74%)

12:24
07/26/17
07/26
12:24
07/26/17
12:24
Conference/Events
Akamai management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 08

    Aug

  • 05

    Sep

MPC

Marathon Petroleum

$56.44

0.42 (0.75%)

12:20
07/26/17
07/26
12:20
07/26/17
12:20
Hot Stocks
Marathon Petroleum raises quarterly dividend 11% to 40c per share »

Marathon Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

$NSD

NASDAQ Market Internals

12:17
07/26/17
07/26
12:17
07/26/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
07/26/17
07/26
12:16
07/26/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSCO

Tractor Supply

$53.53

2.01 (3.90%)

12:15
07/26/17
07/26
12:15
07/26/17
12:15
Options
Tractor Supply put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

BA

Boeing

$230.75

18.29 (8.61%)

, KO

Coca-Cola

$45.36

0.1151 (0.25%)

12:03
07/26/17
07/26
12:03
07/26/17
12:03
General news
On The Fly: Top stock stories at midday »

Stocks opened in positive…

BA

Boeing

$230.75

18.29 (8.61%)

KO

Coca-Cola

$45.36

0.1151 (0.25%)

T

AT&T

$37.84

1.62 (4.47%)

AMD

AMD

$14.11

-0.05 (-0.35%)

TXN

Texas Instruments

$81.39

0.47 (0.58%)

GLW

Corning

$30.29

-1.84 (-5.73%)

GD

General Dynamics

$194.50

-9.06 (-4.45%)

AMGN

Amgen

$180.89

-0.17 (-0.09%)

IRBT

iRobot

$87.90

-2.48 (-2.74%)

AMED

Amedisys

$59.41

0.61 (1.04%)

AFAM

Almost Family

$56.70

-0.15 (-0.26%)

HLS

HealthSouth

$43.48

-2.24 (-4.90%)

KND

Kindred Healthcare

$9.70

-1.5 (-13.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 30

    Jul

  • 01

    Aug

  • 04

    Aug

  • 07

    Aug

  • 08

    Aug

  • 14

    Aug

  • 14

    Aug

  • 15

    Aug

  • 16

    Aug

  • 17

    Aug

  • 23

    Aug

  • 23

    Aug

  • 29

    Aug

  • 07

    Sep

  • 08

    Sep

  • 14

    Sep

  • 16

    Nov

  • 03

    Feb

  • 17

    May

GSM

Ferroglobe

$12.90

0.32 (2.54%)

12:02
07/26/17
07/26
12:02
07/26/17
12:02
Hot Stocks
Ferroglobe has not received regulatory approvals from Spain's water authority »

Ferroglobe announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

MNGA

Magnegas

$0.75

-0.1699 (-18.47%)

12:01
07/26/17
07/26
12:01
07/26/17
12:01
Hot Stocks
USPTO issues MagneGas patent on MagneCule theory »

MagneGas Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$22.77

0.01 (0.04%)

12:00
07/26/17
07/26
12:00
07/26/17
12:00
Options
Post-earnings option play opened in JetBlue »

Post-earnings option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Aug

BA

Boeing

$229.65

17.1924 (8.09%)

11:54
07/26/17
07/26
11:54
07/26/17
11:54
Hot Stocks
Boeing seeing Pentagon demand above Trump's FY18 budget request »

In its Defense, Space…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 07

    Aug

WY

Weyerhaeuser

$34.11

-0.014 (-0.04%)

11:50
07/26/17
07/26
11:50
07/26/17
11:50
Options
Call buyer in Weyerhaeuser ahead of earnings »

Call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

LVMUY

LVMH

$51.12

-0.02 (-0.04%)

11:49
07/26/17
07/26
11:49
07/26/17
11:49
Earnings
LVMH reports first half revenue up 15% to EUR 19.7B »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$229.61

17.15 (8.07%)

11:47
07/26/17
07/26
11:47
07/26/17
11:47
Hot Stocks
Boeing has over '700 firm orders in backlog' for 787 Dreamliner program »

Boeing said its 787…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 07

    Aug

FB

Facebook

$165.28

-0.72 (-0.43%)

11:45
07/26/17
07/26
11:45
07/26/17
11:45
Technical Analysis
Technical Earnings Preview: Facebook in strong uptrend before news »

The stock has been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 13

    Sep

CF

CF Industries

$29.01

-1.16 (-3.84%)

11:45
07/26/17
07/26
11:45
07/26/17
11:45
Options
CF Industries call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

11:45
07/26/17
07/26
11:45
07/26/17
11:45
General news
Treasury's $15 B 2-year FRN garnered decent results »

Treasury's $15 B…

BA

Boeing

$229.09

16.63 (7.83%)

11:43
07/26/17
07/26
11:43
07/26/17
11:43
Hot Stocks
Boeing plans to ramp up production and delivery of new 777X »

Boeing said it has a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 07

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.